averufin profile

averufin: isolated from Aspergillus sp.; has antifungal activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	638296
CHEMBL ID	1706207
CHEBI ID	71537
MeSH ID	M0094932

Synonym
smr000470849
averufin
MLS000563186 ,
7r1n64c5mz ,
unii-7r1n64c5mz
14016-29-6
brn 1299991
(2s)-3,4,5,6-tetrahydro-7,9,11-trihydroxy-2-methyl-2,6-epoxy-2h-anthra(2,3-b)oxocin-8,13-dione
averufine
2,6-epoxy-2h-anthra(2,3-b)oxocin-8,13-dione, 3,4,5,6-tetrahydro-7,9,11-trihydroxy-2-methyl-, (2s)-
NCGC00247578-01
HMS2268O21
CHEBI:71537 ,
CHEMBL1706207
bdbm88955
cid_638296
2'-deoxynidurufin
2,6-epoxy-2h-anthra(2,3-b)oxocin-8,13-dione, 3,4,5,6-tetrahydro-7,9,11-trihydroxy-2-methyl-, (2s,6s)-
DTXSID10891789
Q27139693
(1s,17s)-3,7,9-trihydroxy-17-methyl-16,21-dioxapentacyclo[15.3.1.02,15.04,13.06,11]henicosa-2(15),3,6(11),7,9,13-hexaene-5,12-dione
AKOS040735878

Role	Description
fungal metabolite	Any eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

Class	Description
organic heteropentacyclic compound
polyketide	Natural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides.
cyclic ketal	A ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
polyphenol	Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	35.4813	0.6310	35.7641	100.0000	AID504339
acid sphingomyelinase	Homo sapiens (human)	Potency	316.2280	14.1254	24.0613	39.8107	AID504937
TDP1 protein	Homo sapiens (human)	Potency	29.0929	0.0008	11.3822	44.6684	AID686978; AID686979
PINK1	Homo sapiens (human)	Potency	50.1187	2.8184	18.8959	44.6684	AID624263
isocitrate dehydrogenase 1, partial	Homo sapiens (human)	Potency	50.1187	6.3096	27.0990	79.4328	AID602179
Parkin	Homo sapiens (human)	Potency	50.1187	0.8199	14.8306	44.6684	AID624263
chromobox protein homolog 1	Homo sapiens (human)	Potency	28.1838	0.0060	26.1688	89.1251	AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	79.4328	3.5481	19.5427	44.6684	AID743266
transcriptional regulator ERG isoform 3	Homo sapiens (human)	Potency	11.2202	0.7943	21.2757	50.1187	AID624246
flap endonuclease 1	Homo sapiens (human)	Potency	79.4328	0.1337	25.4129	89.1251	AID588795
serine/threonine-protein kinase PLK1	Homo sapiens (human)	Potency	37.6858	0.1683	16.4040	67.0158	AID720504
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	2.8184	0.4256	12.0591	28.1838	AID504891
DNA polymerase eta isoform 1	Homo sapiens (human)	Potency	19.9526	0.1000	28.9256	213.3130	AID588591
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	25.1189	0.0501	27.0736	89.1251	AID588590
geminin	Homo sapiens (human)	Potency	25.9290	0.0046	11.3741	33.4983	AID624296
DNA dC->dU-editing enzyme APOBEC-3G isoform 1	Homo sapiens (human)	Potency	11.6596	0.0580	10.6949	26.6086	AID602310; AID651812; AID651813
DNA dC->dU-editing enzyme APOBEC-3F isoform a	Homo sapiens (human)	Potency	14.6966	0.0259	11.2398	31.6228	AID602313; AID651814; AID651815
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PSMD14 protein	Homo sapiens (human)	IC50 (µMol)	2.9400	1.3000	21.8715	50.9000	AID602368
TPA: prothrombin	Bos taurus (cattle)	IC50 (µMol)	4.8100	4.8100	36.7432	77.4000	AID602369
72 kDa type IV collagenase isoform 1 preproprotein	Homo sapiens (human)	IC50 (µMol)	78.4000	5.7900	38.9633	78.4000	AID602361
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	6 (25.00)	18.7374
1990's	5 (20.83)	18.2507
2000's	8 (33.33)	29.6817
2010's	4 (16.67)	24.3611
2020's	1 (4.17)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (4.17%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	23 (95.83%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
norsolorinic acid norsolorinic acid: isolated from Aspergillus parasiticus. norsolorinic acid : A polyketide that is anthraquinone bearing four hydroxy substituents at positions 1, 3, 6 and 8 as well as a hexanoyl substituent at position 2.	2.89	4	polyketide; tetrahydroxyanthraquinone	fungal metabolite
o-methylsterigmatocystin [no description available]	2.39	2	sterigmatocystins
versicolorin c versicolorin C: RN given refers to versicolorin C (cis-(+-))-isomer; see also record for versicolorin. versicolorin B : An organic heteropentacyclic compound that is 2,3,3a,12a-tetrahydroanthra[2,3-b]furo[3,2-d]furan-5,10-dione carrying three hydroxy substituents at positions 4, 6 and 8.	2.4	2	cyclic acetal; organic heteropentacyclic compound; p-quinones; polyphenol	Aspergillus metabolite
versiconal hemiacetal acetate versiconal hemiacetal acetate: intermediate in biosynthesis of aflatoxin B1; structure in first source. versiconal hemiacetal acetate : An anthrafuran that is 2,3-dihydroanthra[2,3-b]furan-5,10-dione substituted at positions 2, 4, 6 and 8 by hydroxy groups and at position 3 by a 2-acetoxyethyl group. An intermediate in the biosynthesis of aflatoxin.	2.91	4	acetate ester; anthrafuran; lactol; palmitoyl amino acid; polyphenol	metabolite
dothistromin dothistromin: metabolite of peanut pathogen Cercospora arachidicola; RN given refers to (2R-(2alpha,3abeta,12abeta))-isomer; structure given in first source	1.96	1	anthraquinone
averufanin averufanin: precursor of aflatoxin B1; structure given in first source	7.38	2
versicolorins versicolorins: see also records for versicolorin A & versicolorin C; structure	2.42	2
aflatoxin b1 Aflatoxin B1: A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1.. aflatoxin B1 : An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.	7.66	3	aflatoxin; aromatic ether; aromatic ketone	carcinogenic agent; human metabolite
acetyl coenzyme a Acetyl Coenzyme A: Acetyl CoA participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. It also acts as a biological acetylating agent.	3.12	1	acyl-CoA	acyl donor; coenzyme; effector; fundamental metabolite
versicolorin a versicolorin A: see also versicolorin. versicolorin A : An organic heteropentacyclic compound that is 3a,12a-dihydroanthra[2,3-b]furo[3,2-d]furan-5,10-dione carrying three hydroxy substituents at positions 4, 6 and 8.	2.65	3	cyclic acetal; organic heteropentacyclic compound; p-quinones; polyphenol	Aspergillus metabolite; carcinogenic agent
sterigmatocystin [no description available]	4.33	6	sterigmatocystins	metabolite
averantin averantin: aflatoxin B(1) precursor; structure in first source. averantin : A tetrahydroxyanthraquinone that is 1,3,6,8-tetrahydroxy-9,10-anthraquinone bearing a 1-hydroxyhexyl substituent at position 2.. (S)-averantin : An optically active form of averantin having S-configuration.	2.91	4	averantin
versiconal versiconal: RN not in Chemline 7/83; structure. versiconal : A secondary metabolite that is an intermediate in the biosynthesis of afflatoxin. Can exist as both a tricyclic anthraquinone-hydroxyaldehyde form or as a tetracyclic anthrafuran form.. versiconal hemiacetal : An anthrafuran that is 2,3-dihydroanthra[2,3-b]furan-5,10-dione substituted at positions 2, 4, 6 and 8 by hydroxy groups and at position 3 by a 2-hydroxyethyl group. An intermediate in the biosynthesis of aflatoxin.	2.01	1	anthrafuran; lactol; versiconal
versiconol acetate versiconol acetate: structure given in first source; RN given refers to (-)-isomer; RN for cpd without isomeric designation not avail 2/92. (3S)-versiconol acetate : An optically active form of versiconol acetate having 3S-configuration.. versiconol acetate : An acetate ester that is the O-acetyl derivative of versiconol. An intermediate in the biosynthesis of aflatoxin.	2.42	2	versiconol acetate

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Koch's Disease [description not available]	2.21	1
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	2.21	1

averufin

Description

Cross-References

Synonyms (22)

Roles (1)

Drug Classes (4)

Protein Targets (20)

Potency Measurements

Inhibition Measurements

Bioassays (11)

Research

Studies (24)

Study Types

averufin

Description

Cross-References

Synonyms (22)

Roles (1)

Drug Classes (4)

Protein Targets (20)

Potency Measurements

Inhibition Measurements

Bioassays (11)

Research

Studies (24)

Study Types

Related Drugs (14)

Related Conditions (4)